Design Optimization in Nonlinear Mixed Effects Models Using Cost Functions: Application to a Joint Model of Infliximab and Methotrexate Pharmacokinetics
暂无分享,去创建一个
France Mentré | Sylvie Retout | Emmanuelle Comets | Caroline Bazzoli | F. Mentré | E. Comets | C. Bazzoli | S. Retout
[1] F Mentré,et al. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. , 2005, British journal of clinical pharmacology.
[2] Mats O. Karlsson,et al. Comparison of some practical sampling strategies for population pharmacokinetic studies , 1996, Journal of Pharmacokinetics and Biopharmaceutics.
[3] Ulrich Klotz,et al. Clinical Pharmacokinetics and Use of Infliximab , 2007, Clinical pharmacokinetics.
[4] L. Sheiner,et al. Modelling of individual pharmacokinetics for computer-aided drug dosage. , 1972, Computers and biomedical research, an international journal.
[5] Brian Whiting,et al. Experimental design and efficient parameter estimation in population pharmacokinetics , 1990, Journal of Pharmacokinetics and Biopharmaceutics.
[6] P. Lipsky,et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. , 2000, The Journal of rheumatology.
[7] F. Breedveld,et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.
[8] Marc Lavielle,et al. Maximum likelihood estimation in nonlinear mixed effects models , 2005, Comput. Stat. Data Anal..
[9] Sergei Leonov,et al. OPTIMAL POPULATION DESIGNS FOR PK MODELS WITH SERIAL SAMPLING , 2004, Journal of biopharmaceutical statistics.
[10] Paolo Vicini,et al. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments , 2005, The AAPS Journal.
[11] France Mentré,et al. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model , 2006, Comput. Stat. Data Anal..
[12] Alain Mallet,et al. Optimal design in random-effects regression models , 1997 .
[13] Eric Walter,et al. Identification of Parametric Models: from Experimental Data , 1997 .
[14] France Mentré,et al. Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.
[15] F J Lewis,et al. Continuous patient monitoring with a small digital computer. , 1972, Computers and biomedical research, an international journal.
[16] France Mentré,et al. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..
[17] Malcolm Rowland,et al. Optimal Design for Multivariate Response Pharmacokinetic Models , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[18] A. Mallet. A maximum likelihood estimation method for random coefficient regression models , 1986 .
[19] Valerii V. Fedorov,et al. Design of experiments with unknown parameters in variance , 2002 .
[20] E. Keystone,et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.
[21] France Mentré,et al. Optimization of Individual and Population Designs Using Splus , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[22] Goonaseelan Pillai,et al. Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[23] W. Näther. Optimum experimental designs , 1994 .
[24] D. Bates,et al. Approximations to the Log-Likelihood Function in the Nonlinear Mixed-Effects Model , 1995 .
[25] France Mentré,et al. Design in nonlinear mixed effects models: Optimization using the Fedorov–Wynn algorithm and power of the Wald test for binary covariates , 2007, Statistics in medicine.
[26] W. J. Studden,et al. Theory Of Optimal Experiments , 1972 .
[27] France Mentré,et al. Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.
[28] J. Kremer,et al. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. , 1998, British journal of clinical pharmacology.
[29] T. Louis. Finding the Observed Information Matrix When Using the EM Algorithm , 1982 .
[30] M. Berger,et al. Relative efficiency of unequal cluster sizes for variance component estimation in cluster randomized and multicentre trials , 2008, Statistical methods in medical research.